keyword
MENU ▼
Read by QxMD icon Read
search

pth trials

keyword
https://www.readbyqxmd.com/read/28634117/to-assess-the-effects-of-parathyroidectomy-tptx-versus-tptx-at-for-secondary-hyperparathyroidism-in-chronic-renal-failure-a-meta-analysis
#1
REVIEW
Nian-Cun Qiu, Si-Luo Zha, Miao-E Liu, Zhi-Peng Du, Yi-Fan Wang, Qiang Wang, Qi Chen, Ying Jiang, Cheng-Xiang Shan, Ming Qiu
BACKGROUND: Secondary Hyperparathyroidism (SHPT) requiring parathyroidectomy (PTX) occurs more commonly in patients with progressive chronic kidney disease and in those on long-term lithium therapy. Successful PTX often results in a dramatic drop of parathyroid hormone level, relieves the patient from clinical symptoms, and reduces mortality. However, there is an ongoing debate on the optimal surgical treatment of SHPT. Currently, no clinical guidelines or trials have definitely answered the question of whether Total Parathyroidectomy (TPTX) is superior or equal to Total Parathyroidectomy with Autotransplantation (TPTX + AT)...
June 17, 2017: International Journal of Surgery
https://www.readbyqxmd.com/read/28630081/calcium-sensing-receptor-genotype-and-response-to-cinacalcet-in-patients-undergoing-hemodialysis
#2
Sharon M Moe, Leah Wetherill, Brian Scott Decker, Dongbing Lai, Safa Abdalla, Jin Long, Matteo Vatta, Tatiana M Foroud, Glenn M Chertow
BACKGROUND AND OBJECTIVES: We tested the hypothesis that single nucleotide polymorphisms (SNPs) in the calcium-sensing receptor (CASR) alter the response to the calcimimetic cinacalcet. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We analyzed DNA samples in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial, a randomized trial comparing cinacalcet to placebo on a background of usual care. Of the 3883 patients randomized, 1919 (49%) consented to DNA collection, and samples from 1852 participants were genotyped for 18 CASR polymorphisms...
June 19, 2017: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/28628374/effects-of-a-multispecies-probiotic-supplement-on-bone-health-in-osteopenic-postmenopausal-women-a-randomized-double-blind-controlled-trial
#3
Sadegh Jafarnejad, Kurosh Djafarian, Mohammad Reza Fazeli, Mir Saeed Yekaninejad, Abdolrahman Rostamian, Seyed Ali Keshavarz
OBJECTIVE: The development of alternative approaches to prevent and/or treat osteoporosis, as a chronic progressive bone disease, is being considered currently. Among dietary supplements, probiotics may have favorable effects on bone metabolism. Therefore, the aim of this study was to evaluate the effects of a multispecies probiotic supplementation on bone biomarkers and bone density in osteopenic postmenopausal women. METHODS: This randomized double-blind placebo-controlled clinical trial was performed on 50 patients with osteopenia aged 50-72 years...
June 19, 2017: Journal of the American College of Nutrition
https://www.readbyqxmd.com/read/28621627/factors-associated-with-shunt-dependent-hydrocephalus-after-decompressive-craniectomy-for-traumatic-brain-injury
#4
Aditya Vedantam, Jose-Miguel Yamal, Hyunsoo Hwang, Claudia S Robertson, Shankar P Gopinath
OBJECTIVE Posttraumatic hydrocephalus (PTH) affects 11.9%-36% of patients undergoing decompressive craniectomy (DC) and is an important cause of morbidity after traumatic brain injury (TBI). Early diagnosis and treatment of PTH can prevent further neurological compromise in patients who are recovering from TBI. There is limited data on predictors of shunting for PTH after DC for TBI. METHODS Prospectively collected data from the erythropoietin severe TBI randomized controlled trial were studied. Demographic, clinical, and imaging data were analyzed for enrolled patients who underwent a DC...
June 16, 2017: Journal of Neurosurgery
https://www.readbyqxmd.com/read/28606219/dietary-calcium-intake-and-rate-of-bone-loss-in-men
#5
Sarah M Bristow, Gregory D Gamble, Anne M Horne, Ian R Reid
A high Ca intake has been recommended for osteoporosis prevention; however, little research has examined the relationship between dietary Ca and bone health in men. We examined associations between dietary Ca intake, bone mineral density (BMD) and change in BMD at the total body, hip and spine over 2 years in a cohort of men (mean age 57 years, BMI 26 kg/m2) from a trial. Data from the total cohort (n 323) were used in the analysis of Ca intake and BMD at baseline, and data from the placebo group (n 99) were used in the longitudinal analysis of Ca intake and change in BMD...
June 13, 2017: British Journal of Nutrition
https://www.readbyqxmd.com/read/28579423/serum-phosphorus-and-risk-of-cardiovascular-disease-all-cause-mortality-or-graft-failure-in-kidney-transplant-recipients-an-ancillary-study-of-the-favorit-trial-cohort
#6
Basma Merhi, Theresa Shireman, Myra A Carpenter, John W Kusek, Paul Jacques, Marc Pfeffer, Madhumathi Rao, Meredith C Foster, S Joseph Kim, Todd E Pesavento, Stephen R Smith, Clifton E Kew, Andrew A House, Reginald Gohh, Daniel E Weiner, Andrew S Levey, Joachim H Ix, Andrew Bostom
BACKGROUND: Mild hyperphosphatemia is a putative risk factor for cardiovascular disease [CVD], loss of kidney function, and mortality. Very limited data are available from sizable multicenter kidney transplant recipient (KTR) cohorts assessing the potential relationships between serum phosphorus levels and the development of CVD outcomes, transplant failure, or all-cause mortality. STUDY DESIGN: Cohort study. SETTING & PARTICIPANTS: The Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial, a large, multicenter, multiethnic, controlled clinical trial that provided definitive evidence that high-dose vitamin B-based lowering of plasma homocysteine levels did not reduce CVD events, transplant failure, or total mortality in stable KTRs...
June 2, 2017: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/28565886/effects-of-cholecalciferol-supplementation-in-patients-with-stable-heart-failure-and-low-vitamin-d-levels-ecsploit-d-a-double-blind-randomized-placebo-controlled-pilot-study
#7
Fabrizio Turrini, Stefania Scarlini, Paolo Giovanardi, Roberto Messora, Laura Roli, Johanna Chester, Chiara Mussi, Marco Bertolotti, Tommaso Trenti, Marco Bondi
BACKGROUND: The aim of this study was to investigate the effects of vitamin D (VD) on the interaction among functional, echocardiographic and hormonal parameters in patients with heart failure (HF) and VD deficiency. METHODS: In a randomized, double blind trial, 35 patients with HF and VD < 20 ng/ml, received either 300,000 U of oral cholecalciferol followed by 50,000 U/month for 6 months, or placebo treatment. RESULTS: Changes in the 6 Minute Walking Test (6MWT) assessed at 3 and 6 months in treatment group was the primary end point...
May 31, 2017: Minerva Cardioangiologica
https://www.readbyqxmd.com/read/28550081/randomized-controlled-trial-for-the-effect-of-vitamin-d-supplementation-on-vascular-stiffness-in-ckd
#8
Adeera Levin, Mila Tang, Taylor Perry, Nadia Zalunardo, Monica Beaulieu, Joshua A Dubland, Kelly Zerr, Ognjenka Djurdjev
BACKGROUND AND OBJECTIVES: Vitamin D is implicated in vascular health in CKD. This study compared placebo, calcifediol, and calcitriol treatment with changes in vascular stiffness, BP, proteinuria, mineral metabolism parameters, C-reactive protein, and fibroblast growth factor 23 in patients with stable CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a double-blind, randomized controlled trial in outpatient CKD clinics in Vancouver, Canada, from February of 2011 to August of 2014, enrolling 119 patients with an eGFR of 15-45 ml/min per 1...
May 26, 2017: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/28528472/early-prediction-of-hypocalcemia-following-thyroid-surgery-a-prospective-randomized-clinical-trial
#9
Alessandra Saba, Mauro Podda, Antonio Messina Campanella, Adolfo Pisanu
PURPOSE: The aim of this randomized-controlled trial was to validate the results of a previous prospective single-cohort observational study conducted in the same surgical unit regarding the use of concomitant intact parathyroid hormone (iPTH) and serum calcium measurement in predicting hypocalcemia after total thyroidectomy. METHODS: From January 2014 to January 2015, 150 patients underwent total thyroidectomy in our department and were randomized into two groups...
May 20, 2017: Langenbeck's Archives of Surgery
https://www.readbyqxmd.com/read/28522130/primary-hyperparathyroidism-hypercalciuria-and-bone-recovery-after-parathyroidectomy
#10
Inga-Lena Nilsson, Sophie Norenstedt, Jan Zedenius, Ylva Pernow, Robert Bränström
BACKGROUND: In primary hyperparathyroidism, successful parathyroidectomy leads to improved bone mineral density in the majority of cases. Our aim was to further explore the relationship between hypercalciuria, kidney function, and bone recovery after parathyroidectomy. METHODS: Bone mineral density, estimated glomerular filtration rate, and 24-hour urinary calcium were analyzed before and one year after parathyroidectomy in a cohort of 150 primary hyperparathyroidism patients (119 women; median age 60 [range 30-80] years) taking part in a clinical trial...
May 15, 2017: Surgery
https://www.readbyqxmd.com/read/28521692/pharmacological-treatment-of-bone-loss
#11
Rui Pang, Weibo Xia
Bone loss is common in clinical practice, such as health assessment of postmenopausal women, treatment of tumor metastasis, side-effects of glucocorticoids, and skeletal manifestations of inflammatory diseases. The imbalance of remodeling between bone resorption and bone formation, the pathophysiological basis of bone loss, increases bone fragility. The treatment of bone loss is mainly carried out from the treatment of osteoporosis. There are various pharmacological therapies for bone loss, which will be introduced in 3 aspects, including anti-resorptive agents, anabolic agents and new medications...
May 16, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/28509078/the-effects-of-vitamin-d-supplementation-on-proatherogenic-inflammatory-markers-and-carotid-intima-media-thickness-in-subjects-with-metabolic-syndrome-a-randomized-double-blind-placebo-controlled-clinical-trial
#12
Shabnam Salekzamani, Abolhassan Shakeri Bavil, Hossein Mehralizadeh, Mohammad Asghari Jafarabadi, Aymaral Ghezel, Bahram Pourghassem Gargari
PURPOSE: Metabolic syndrome may predispose to cardiovascular diseases. Since, in recent studies, vitamin D is advocated for cardioprotective roles, this study was designed to investigate the effects of vitamin D supplementation on proatherogenic inflammatory markers and common carotid intima media thickness in subjects with metabolic syndrome. METHODS: This randomized double blind clinical trial was conducted in Tabriz, Iran. Eligible subjects (n = 80) with metabolic syndrome were recruited thorough advertisement and randomized to receive either vitamin D (50,000 IU/week) or matching placebo for 16 weeks...
May 16, 2017: Endocrine
https://www.readbyqxmd.com/read/28508378/population-pharmacokinetic-and-pharmacodynamic-modeling-of-etelcalcetide-in-patients-with-chronic-kidney-disease-and-secondary-hyperparathyroidism-receiving-hemodialysis
#13
Ping Chen, Adimoolam Narayanan, Benjamin Wu, Per Olsson Gisleskog, John P Gibbs, Andrew T Chow, Murad Melhem
INTRODUCTION: Etelcalcetide is a novel calcimimetic that binds and activates calcium-sensing receptors (CaSRs) for the treatment of secondary hyperparathyroidism (SHPT). METHODS: To assess titrated dosing regimens, population pharmacokinetic (PK) and PK/pharmacodynamic (PKPD) modeling of etelcalcetide was performed using NONMEM 7.2. In this analysis, plasma etelcalcetide, serum parathyroid hormone (PTH) and calcium (Ca) concentration-time data were collected from five phase I, II, and III clinical trials following single or multiple intravenous doses of etelcalcetide ranging from 2...
May 15, 2017: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/28499709/mortality-in-dialysis-patients-with-cinacalcet-use-a-large-observational-registry-study
#14
Claudia Friedl, Gilbert Reibnegger, Reinhard Kramar, Emanuel Zitt, Stefan Pilz, Johannes F E Mann, Alexander R Rosenkranz
BACKGROUND: Secondary hyperparathyroidism (sHPT) is associated with higher mortality in dialysis patients. The calcimimetic cinacalcet reduces intact parathyroid hormone (iPTH) in dialysis patients. The randomized controlled EVOLVE trial failed to unequivocally prove survival advantage of cinacalcet in dialysis patients. However, recent post hoc analyses suggested a benefit in subgroups of dialysis patients. Large observational cohort studies may represent an option to better determine such subgroups...
May 9, 2017: European Journal of Internal Medicine
https://www.readbyqxmd.com/read/28495640/sources-of-hematopoietic-stem-and-progenitor-cells-and-methods-to-optimize-yields-for-clinical-cell-therapy
#15
REVIEW
Sandhya R Panch, James Szymanski, Bipin N Savani, David F Stroncek
Bone marrow (BM) aspirates, mobilized peripheral blood, and umbilical cord blood (UCB) have developed as graft sources for hematopoietic stem and progenitor cells (HSPCs) for stem cell transplantation and other cellular therapeutics. Individualized techniques are necessary to enhance graft HSPC yields and cell quality from each graft source. BM aspirates yield adequate CD34(+) cells but can result in relative delays in engraftment. Granulocyte colony-stimulating factor (G-CSF)-primed BM HSPCs may facilitate faster engraftment while minimizing graft-versus-host disease in certain patient subsets...
May 8, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28451892/oral-paricalcitol-expanding-therapeutic-options-for-pediatric-chronic-kidney-disease-patients
#16
EDITORIAL
Michael Freundlich, Carolyn L Abitbol
The complex pathophysiology of progressive chronic kidney disease (CKD) and the development of mineral and bone disorder, abbreviated as CKD-MBD, is of vital importance to a pediatric patient. Paricalcitol, the 19 nor-1,25(OH)2D2 analogue was shown to be effective and safe in the treatment of secondary hyperparathyroidism (SHPT) in adults almost two decades ago. It also significantly improved survival in dialysis patients compared to the standard calcitriol. The successful treatment of CKD-MBD in children is essential if they are to grow and survive into adulthood...
April 27, 2017: Pediatric Nephrology: Journal of the International Pediatric Nephrology Association
https://www.readbyqxmd.com/read/28436117/early-introduction-of-oral-paricalcitol-in-renal-transplant-recipients-an-open-label-randomized-study
#17
Hege Kampen Pihlstrøm, Franscesca Gatti, Clara Hammarström, Ivar Anders Eide, Monika Kasprzycka, Junbai Wang, Guttorm Haraldsen, My Hanna Sofia Svensson, Karsten Midtvedt, Geir Mjøen, Dag Olav Dahle, Anders Hartmann, Hallvard Holdaas
In stable renal transplant recipients with hyperparathyroidism, previous studies have indicated that vitamin D agonist treatment might have anti-proteinuric effects. Animal studies indicate possible anti-fibrotic and anti-inflammatory effects. Early introduction of paricalcitol in de novo renal transplant recipients might reduce proteinuria and prevent progressive allograft fibrosis. We performed a single-center, prospective, randomized, open-label trial investigating effects of paricalcitol 2 μg/day added to standard care...
April 24, 2017: Transplant International: Official Journal of the European Society for Organ Transplantation
https://www.readbyqxmd.com/read/28433267/dose-response-effects-of-supplementation-with-calcifediol-on-serum-25-hydroxyvitamin-d-status-and-its-metabolites-a-randomized-controlled-trial-in-older-adults
#18
Anouk M M Vaes, Michael Tieland, Margot F de Regt, Jonas Wittwer, Luc J C van Loon, Lisette C P G M de Groot
BACKGROUND & AIMS: Oral supplementation with vitamin D is recommended for older adults to maintain a sufficient 25-hydroxyvitamin D (25(OH)D) status throughout the year. While supplementation with vitamin D2 or D3 is most common, alternative treatment regimens exist which require further investigation with respect to increasing 25(OH)D concentration. We investigated the dose-response effects of supplementation with calcifediol compared to vitamin D3 and assessed the dose which results in mean serum 25(OH)D3 concentrations between 75 and 100 nmol/L...
March 31, 2017: Clinical Nutrition: Official Journal of the European Society of Parenteral and Enteral Nutrition
https://www.readbyqxmd.com/read/28432842/low-grade-inflammation-and-tryptophan-kynurenine-pathway-activation-are-associated-with-adverse-cardiac-remodeling-in-primary-hyperparathyroidism-the-epath-trial
#19
Nicolas Verheyen, Andreas Meinitzer, Martin Robert Grübler, Klemens Ablasser, Ewald Kolesnik, Astrid Fahrleitner-Pammer, Evgeny Belyavskiy, Christian Trummer, Verena Schwetz, Elisabeth Pieske-Kraigher, Jakob Voelkl, Ioana Alesutan, Cristiana Catena, Leonardo Alberto Sechi, Helmut Brussee, Dirk von Lewinski, Winfried März, Burkert Pieske, Stefan Pilz, Andreas Tomaschitz
BACKGROUND: Primary hyperparathyroidism (pHPT) is associated with low-grade inflammation, left ventricular hypertrophy and increased cardiovascular mortality, but the association between inflammatory markers and parameters of adverse cardiac remodeling is unknown. We investigated the relationship between C-reactive protein (CRP), the essential amino acid tryptophan and its pro-inflammatory derivatives kynurenine and quinolinic acid (QUIN) with echocardiographic parameters. METHODS: Cross-sectional baseline data from the "Eplerenone in Primary Hyperparathyroidism" trial were analyzed...
April 22, 2017: Clinical Chemistry and Laboratory Medicine: CCLM
https://www.readbyqxmd.com/read/28429905/maintenance-vitamin-d3-dosage-requirements-in-chinese-women-with-post-menopausal-osteoporosis-living-in-the-tropics
#20
Yogeswari Venugopal, Sharifah F Wan Muhamad Hatta, Nurbazlin Musa, Siti Abdul Rahman, Jeyakantha Ratnasingam, Sharmila Sunita Paramasivam, Lee Ling Lim, Luqman Ibrahim, Karen Choong, Alexander Tb Tan, Karuthan Chinna, Siew Pheng Chan, Shireene R Vethakkan
BACKGROUND AND OBJECTIVES: Vitamin D3 (cholecalciferol) dose required to maintain sufficiency in non- Caucasian women with postmenopausal osteoporosis (PMO) inthe tropics has not been well studied. Some guidelines mandate 800-1000 IU vitamin D/day but the Endocrine Society (US) advocates 1500-2000 IU/day to maintain 25-hydroxyvitamin-D (25(OH)D) concentration at >75 nmol/L. We aimed to establish oral cholecalciferol dose required to maintain 25(OH)D concentration at >75 nmol/L in PMO Chinese Malaysian women, postulating lower dose requirements amongst light-skinned subjects in the tropics...
May 2017: Asia Pacific Journal of Clinical Nutrition
keyword
keyword
95204
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"